Search Results
Your search for all items matches 34717 pages
Showing 30401 - 30450Practice-Changing Study: Pembrolizumab Outperforms Ipilimumab in Advanced Melanoma
Pembrolizumab (Keytruda) proved superior to ipilimumab (Yervoy) for the treatment of unresectable advanced melanoma in the global phase III KEYNOTE-006 trial. Pembrolizumab significantly improved overall survival, progression-free survival, and overall response rate compared with ipilimumab, which...
Profile: Julie M. Vose, MD, MBA, FASCO, Making a Difference in Both Clinical Medicine and Research
At this year’s ASCO Annual Meeting, Julie M. Vose, MD, MBA, FASCO, will begin her term as the Society’s 51st President. It is fitting that the meeting will be held in Chicago, the city where the first seven visionaries met over lunch in 1964 to formulate a medical organization centered on cancer...
HOPA Announces New President and 2015 Membership Award Winners
The Hematology/Oncology Pharmacy Association (HOPA) has elected Scott Soefje, PharmD, MBA, BCOP, FCCP, to serve as President for the 2015–2016 term. His term began at the 11th HOPA Annual Conference, held March 25–28. Dr. Soefje has served as President-Elect since March 2014. Dr. Soefje is a...
p53 Takes Center Stage
BOOKMARKTitle: p53: The Gene That Cracked the Cancer CodeAuthor: Sue ArmstrongPublisher: Bloomsbury PublishingPublication date: November 20, 2014Price: $19.98; hardcover, 288 pages Completed in April 2003, the Human Genome Project was one of the greatest feats of scientific exploration, an inward ...
Nicholas J. Petrelli, MD, Receives Service Award
Nicholas J. Petrelli, MD, Bank of America Endowed Medical Director of the Helen F. Graham Cancer Center & Research Institute at Christiana Care Health System, received the 2015 Service Award from the Delaware Bio Science Association. Delaware Bio Science is a trade association focused solely on ...
Cancer Survivors: Facts and Figures
The National Cancer Institute’s Office of Cancer Survivorship recently issued the following data: As of January 2014, it is estimated that there are 14.5 million cancer survivors in the United States. This represents over 4% of the population, according to a report published recently.1 The...
People Living With HIV in the United States Have a 50% Excess Cancer Risk
The nearly 900,000 people in the United States living with diagnosed human immunodeficiency virus (HIV) infection have an excess cancer risk of 50%, according to a joint analysis of data by the National Cancer Institute and the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention,...
Therapy for Hepatitis C Virus Infection in Patients With Cancer May Prevent Liver Disease Progression
“Hepatitis C virus (HCV) infection is a neglected disease in patients with cancer,” Harrys A. Torres, MD, and colleagues from the University of Texas MD Anderson Cancer Center in Houston noted in the Journal of the National Comprehensive Cancer Network. To rectify that situation, the researchers...
EGFR L858R Mutation in Blood Sample May Serve as Surrogate for Biopsy in Determining EGFR-Mutation Status
Using a novel polymerase chain reaction assay “to efficiently assess” epidermal growth factor receptor (EGFR) mutations in circulating free DNA (cfDNA) from blood samples of patients with advanced non–small cell lung cancer (NSCLC), the Spanish Lung Cancer Group has “shown that the EGFR L858R...
Prior Cancer Does Not Affect Outcomes Among Patients With Advanced Lung Cancer, Suggesting They Be Included in Clinical Trials
Analysis of data from 102,929 patients with stage IV lung cancer found that “prior cancer does not convey an adverse effect on clinical outcomes, regardless of prior cancer stage, type, or timing.” Based on these findings, investigators from the Harold C. Simmons Cancer Center, University of Texas...
Emergency Room Visits and Hospitalizations Are Common Among Women With Early Breast Cancer Receiving Chemotherapy
Emergency room visits and hospitalizations are common among patients with early breast cancer receiving chemotherapy, particularly among those receiving a regimen containing docetaxel, according to a study supported by the Ontario Institute of Cancer Research, Toronto. “In this population-based...
Expect Questions About Physical Activity and Reduced Mortality Risks
A study finding that just doing some leisure time physical activity reduces overall and cancer-specific mortality by 20% and that more activity can provide even greater survival benefits concludes that health-care professionals should encourage inactive patients to perform more leisure time...
Just Engaging in ‘Some’ Leisure Time Physical Activity Reduces Overall and Cancer-Specific Mortality
There’s good news for those who recognize the benefits of exercise but feel they have neither the time nor energy for frequent workouts: A recent study reported in JAMA Internal Medicine1 has found that just performing “some” leisure time physical activity, even below the recommended minimum level, ...
Article on Rare Cancer Generates Enthusiastic Response
The article “Shining a Spotlight on Epithelioid Hemangioendothelioma,” written by Jane Gutkovich and published in the April 10, 2015, issue of The ASCO Post, generated an enthusiastic response from the patient and advocate community of individuals with this rare cancer. Here, we are pleased to...
Remembering Mark R. Green, MD, a Leader in Lung Cancer Research and Treatment
Few people have impacted cancer clinical research in the past quarter century as much as Mark Green. His expertise in lung cancer and clinical trial design led to the successful completion of seminal studies combining radiation and chemotherapy that forever changed the management of patients with...
Andrew Parsa, MD, PhD, Chair of Neurological Surgery at Northwestern, Dies at 48
Andrew Parsa, MD, PhD, the Michael J. Marchese Professor and Chair of the Departments of Neurological Surgery at Feinberg and Northwestern Memorial Hospital, passed away on April 13. He was 48 years old. “We are all shocked and saddened by this great loss. Dr. Parsa was a distinguished scholar, an...
Remembering Multiple Myeloma Patient Advocate Michael S. Katz, MBA
I first met Michael Katz, MBA, in 2004, 3 years after my brother, Dom, was diagnosed with multiple myeloma, and we were at a crossroads in his care and needed advice. Although an experimental regimen of thalidomide (Thalomid) and dexamethasone had successfully put Dom in remission for a year (the...
EGFR Amplification/Overexpression Associated With Improved Response of Glioblastoma to Metronomic Temozolomide
In a study reported in Journal of the National Cancer Institute, Cominelli and colleagues found that EGFR amplification/overexpression was associated with improved response of glioblastoma to adjuvant metronomic (every day of a 28 day cycle at a dosing of 50-75 mg/m2) but not standard (5...
IGF2 May Be Target in Colorectal Cancer With Stable Disease As Response to Anti-EGFR Therapy
In a study exploring the mechanisms of stabilized disease vs tumor regression with targeted anti–epidermal growth factor receptor (EGFR) therapy in colorectal cancer reported in Science Translational Medicine, Zanella and colleagues found that stable disease as response was characterized by...
Bispecific Antibody Recruitment to Increase Antitumor Activity of Adoptive T-Cell Transfer
In a study reported in the Journal of the National Cancer Institute, Kobold and colleagues assessed whether combining tumor-specific T cells modified with a marker antigen and a bispecific antibody that selectively recognizes transduced T cells and tumor cells could improve T-cell recruitment to...
The Paradox of Positive Thinking
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology (JCO). These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Unexpectedly Huge Survival Benefit With Pertuzumab and Trastuzumab in HER2-Positive Metastatic Breast Cancer
In my opinion, the combination of pertuzumab (Perjeta) and trastuzumab (Herceptin) is one of the most important advances in the field of metastatic breast cancer in the past 10 years. As recently reported by Swain, my other colleagues, and me and reviewed in this issue of The ASCO Post, the...
CLEOPATRA Overall Survival Analysis: Significant Benefit for Pertuzumab Plus Trastuzumab/Docetaxel in HER2-Positive Metastatic Breast Cancer
As reported in The New England Journal of Medicine by Sandra M. Swain, MD, of Washington Cancer Institute, MedStar Washington Hospital Center, and colleagues, the final prespecified overall survival analysis in the phase III CLEOPATRA study showed a significant 15.7-month increase in median overall ...
Steps to More Effective Communication
Alan Alda, Co-Founder of the Alan Alda Center for Communicating Science and Visiting Professor at Stony Brook University, suggests these steps to improve scientific communication. The ability to be empathic and imagine what someone else might be thinking or feeling is the key to becoming a more...
Learning to Communicate Science More Effectively
Alan Alda’s passion and appreciation for science extend nearly as far back to his early life as his love of acting. The son of actor Robert Alda, Mr. Alda began his acting career at the age of 16. Although he has appeared in such widely acclaimed films as The Seduction of Joe Tynan, Crimes and...
Patient Guides Available Through ASCO University Bookstore
ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...
Living With a Rare Cancer—My Dr. Seuss World
No one ever expects to hear the words “you have cancer,” but over the course of the day, over 5,000 people in the United States are given that news.1 I first heard those words in the summer of 2007 and have been living with cancer ever since. At the time of my diagnosis, I knew this would forever...
Courage Under Fire
The following essay by Kishore K. Dass, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org. Born in...
A Less Is More View of Medicine
BOOKMARKTitle: Less Medicine, More Health: 7 Assumptions That Drive Too Much Medical CareAuthor: H. Gilbert Welch, MDPublisher: Beacon PressPublication date: March 3, 2015Price: $24.95; hardcover, 241 pages He’s the best physician that knows the worthlessness of most medicines. —Benjamin Franklin...
2015 Oncology Meetings
MAY American Association for Cancer Research: Advances in Brain Cancer ResearchMay 27-30 • Washington, DC For more information: www.aacr.org ASCO Annual MeetingMay 29-June 2 • Chicago, Illinois For more information: am.asco.org 2015 ASCO State Affiliates’ ReceptionMay 31 • Chicago, Illinois For...
Building a Better Federal Oncology Workforce
The process of delivering novel treatments for patients with cancer involves a multifaceted and long-term interaction between three distinct entities: clinical researchers, who conduct the trials which test treatments; drug developers, including the pharmaceutical industry, which takes cancer drugs ...
The Mechanisms Driving Cancer Pain
For over a decade, Patrick W. Mantyh, PhD, JD, has been investigating the molecular and cellular mechanisms that are involved in cancer-related pain, especially bone pain caused by advanced breast, prostate, and lung cancers. His early laboratory work using mouse models of bone cancer led to an...
8 Steps to Help Children Cope With Cancer and Its Treatment
Here are several steps for helping pediatric and adolescent patients to cope with cancer and its treatment. Give young patients control whenever possible, suggests Shawna Grissom, MS, CCLS, CEIM, Director of the Child Life Program at St. Jude Children’s Research Hospital, and offer them realistic...
Taking the Trauma Out of Cancer Care for Children and Adolescents
Getting a cancer diagnosis and going through treatment are difficult for patients of any age, but the experience can be especially traumatizing for the nearly 16,000 infants, children, and adolescents diagnosed each year with cancer,1 especially during the early days of treatment. Young cancer...
Sarcoma of the Arm, Circa 1874
The text and photographs on this page are excerpted from a four-volume series of books titled Oncology Tumors & Treatment: A Photographic History, by Stanley B. Burns, MD, FACS. The photos below are from the volume titled “The Anesthesia Era: 1845–1875.” To view additional photos from this...
ASCO, ACCC Respond to Repeal of Medicare Sustainable Growth Rate Formula
The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) responded to the approval of H.R.2, a Medicare-reform bill to end the program’s sustainable growth rate (SGR) formula. ASCO’s Statement ASCO President Peter Paul Yu, MD, FACP, FASCO, praised the ...
Cobas KRAS Mutation Test Receives FDA Approval
Roche announced that the U.S. Food and Drug Administration (FDA) has approved the cobas KRAS Mutation Test for diagnostic use. The real-time polymerase chain reaction (PCR) test is designed to identify KRAS mutations in tumor samples from patients with metastatic colorectal cancer and aid...
FDA Accepts Supplemental Biologics License Application for Nivolumab in Patients With Previously Untreated Advanced Melanoma
The U.S. Food and Drug Administration (FDA) has accepted for filing and review Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for nivolumab (Opdivo) for the treatment of previously untreated patients with unresectable or metastatic melanoma. The FDA also granted Priority...
Clinical Trials Actively Recruiting Patients With Cutaneous Lymphoma
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies for patients with newly diagnosed or relapsed or refractory lymphoma of the skin. The studies include observational, phase I, and phase II trials investigating single-agent and...
In Search of Meaning: A Personal Journey
A famous Talmudic question asks: “What is truer than the truth?” The answer: “The story.” This is the story of my personal journey in search of meaning and the development of an approach to care for patients with advanced cancer, which I came to call “meaning-centered psychotherapy.” In terms of...
Ramucirumab With FOLFIRI in Metastatic Colorectal Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On April 24, the monoclonal antibody ramucirumab (Cyramza) was...
FDA Grants Fast Track Designation to Evofosfamide for Advanced Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of evofosfamide (TH-302), administered in combination with gemcitabine, for previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer. Evofosfamide is an...
Venetoclax Receives Breakthrough Therapy Designation in Relapsed/Refractory CLL With 17p Deletion
The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to AbbVie’s investigational agent venetoclax (ABT-199) for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) in patients with 17p deletion. Venetoclax is an investigational oral B-cell...
Mario R. Capecchi, PhD, Recognized With AACR Lifetime Achievement in Cancer Research Award
Mario R. Capecchi, PhD, was honored for his tremendous scientific contributions, which have had a profound impact on the understanding of cancer, with the 12th annual American Association for Cancer Research (AACR) Award for Lifetime Achievement in Cancer Research at the AACR Annual Meeting 2015....
Pembrolizumab vs Ipilimumab: Good vs Better
The treatment landscape for metastatic melanoma has recently undergone a remarkable transformation. Prior to 2011, clinicians and patients were presented with difficult decisions between therapies without proven survival benefit. Now, similarly difficult but much more hopeful choices are posed...
Anti–PD-1 Antibody Pembrolizumab Improves Progression-Free and Overall Survival vs Ipilimumab in Advanced Melanoma
In the phase III KEYNOTE-006 trial reported in The New England Journal of Medicine,1 Caroline Robert, MD, PhD, Head of the Dermatology Unit at the Institut Gustave Roussy, Paris, and colleagues found that the anti–programmed cell death protein 1 (PD-1) antibody pembrolizumab (Keytruda) increased...
Guidelines for the Treatment of Older Cancer Patients: Task Forces of the International Society of Geriatric Oncology
Geriatrics for the Oncologist is guest edited by Stuart Lichtman, MD, FACP, FASCO, and developed in collaboration with the International Society of Geriatric Oncology (SIOG). Visit SIOG.org for more on geriatric oncology. The Task Forces of the International Society of Geriatric Oncology (SIOG) are ...
Potential Power of Meaning-Centered Group Psychotherapy in Patients With Advanced Cancer
The recent publication of the results of our National Cancer Institute (NCI) RO1-funded randomized controlled trial of meaning-centered group psychotherapy for advanced cancer patients in the Journal of Clinical Oncology,1 and the accompanying summary published in this issue of The ASCO Post,...
Meaning-Centered Group Psychotherapy Improves Psychological Well-Being in Patients With Advanced Cancer
In a randomized trial reported in the Journal of Clinical Oncology, William Breitbart, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that meaning-centered group psychotherapy significantly improved psychological well-being compared with supportive group psychotherapy in...
James Allison, PhD, Receives 2015 AACR Pezcoller Award
James Allison, PhD, was named a recipient of the 2015 Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Cancer Research at the 2015 AACR Annual Meeting. Dr. Allison, Chair of Immunology at The University of Texas MD Anderson Cancer Center, was acknowledged ...
